Vaccinating young adults against human papillomavirus: the importance of understanding health decision-making and behaviour

Sexual Health ◽  
2007 ◽  
Vol 4 (2) ◽  
pp. 129 ◽  
Author(s):  
S. Rachel Skinner ◽  
Melissa Kang ◽  
Susan L. Rosenthal
Keyword(s):  
Human Papillomavirus ◽  
Hpv Vaccine ◽  
Hpv Vaccination ◽  
Initial Study ◽  
Quadrivalent Vaccine ◽  
Age Group ◽  
Vaccine Acceptability ◽  
Health Decision Making ◽  
Health Decision ◽  
Hpv Vaccine Acceptability

Vaccination of young teenage females against human papillomavirus (HPV) with a newly licenced quadrivalent vaccine designed to prevent cervical cancer and genital warts has recently been recommended by the Australian government and will be implemented through schools from April 2007. In addition, a fully funded ‘catch-up’ vaccination program for young women up to age 26 years has been approved for a 2-year period, from July 2007. As general practitioners (GPs) will be the main immunisation providers for this age group, in order to achieve high vaccination coverage and maximal impact on disease, it will be critical for GPs to be opportunistic in recommending this vaccine. An initial study of young Australians’ attitudes towards HPV vaccination and hypothetical acceptance of the vaccine was published in this journal. We draw on this study and data published elsewhere to discuss issues of HPV vaccine acceptability, and the likely challenges of a mass vaccination initiative in this age group in Australia. We suggest specific strategies to support GPs, and highlight areas for further research in HPV vaccine acceptability.

scholarly journals Introduction of HPV vaccination in Kenya

Afrika Focus ◽  
2016 ◽  
Vol 29 (2) ◽  
Author(s):  
Heleen Vermandere
Keyword(s):  
Cervical Cancer ◽  
Hpv Vaccine ◽  
Hpv Vaccination ◽  
Organizational Factors ◽  
Personal Control ◽  
Vaccine Uptake ◽  
Vaccine Hesitancy ◽  
Open Communication ◽  
Vaccine Acceptability ◽  
Hpv Vaccine Acceptability

HPV vaccination prevents cervical cancer, the fourth most common cancer among women worldwide. Measured HPV vaccine acceptability is often high but does it also lead to high uptake? Methodology: A cohort was set up assessing HPV vaccine acceptability and other health behav- iour constructs before, and vaccine uptake after an HPV vaccination programme in Eldoret, Kenya. Focus groups shed light on the motivation for vaccine uptake or refusal. Results: Acceptability was high but was no strong predictor of uptake, and neither were the constructs of the Health Belief Model. Lack of information and fear of side effects were major barriers. Feeling uncomfortable to discuss cervical cancer hampered open communication. Discussion: Distrust towards new vaccines and the health system blocked translation from willingness-to-vaccinate to actual uptake, as did organizational factors such as poor promotion. Conclusion: Future research should include broader concepts such as vaccine hesitancy and factors beyond personal control in order to predict vaccine uptake. Key words: HPV vaccination, acceptability, uptake, longitudinal study, Kenya 

scholarly journals Improvement of Parent’s awareness, knowledge, perception, and acceptability of human papillomavirus vaccination after a structured-educational intervention

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Mei Neni Sitaresmi ◽  
Nisrina Maulida Rozanti ◽  
Lamria Besty Simangunsong ◽  
Abdul Wahab
Keyword(s):  
Educational Intervention ◽  
Hpv Vaccine ◽  
Hpv Vaccination ◽  
Hpv Infection ◽  
Primary School Students ◽  
School Students ◽  
Demonstration Program ◽  
Vaccine Acceptability ◽  
Parental Awareness ◽  
Hpv Vaccine Acceptability

Abstract Background Regardless of the disease burden of human papillomavirus (HPV), the vaccine has not been included in the Indonesia National Immunization Program. Since 2017 there was a demonstration program of the HPV vaccination in Yogyakarta Province. This vaccine was given free to female primary school students in the 5th and 6th grades (11–13 years old). This study aimed to assess whether a structured-educational intervention focus on HPV increases the parental awareness, knowledge, and perceptions toward HPV and the vaccine acceptability. Methods We conducted a pre-post structured-educational intervention study from July to August 2017 before the implementation of the HPV vaccination demonstration program, in Kulon Progo District, Yogyakarta Province, Indonesia. Parents of female primary school students grades 5th and 6th were selected using a school-based proportional random sampling. A pediatric resident provided a structured-educational intervention, which consists of the burden and risk of HPV disease, as well as the benefit and safety of the vaccine. Parents were required to complete validated self-administered questionnaires before and after the structured-educational intervention. Results A total of 506 parents participated. Before receiving the structured-educational intervention, parents’ awareness of HPV infection and the vaccines were low. Only 49.2% of parents had heard HPV infection, and 48.8% had heard about the vaccine. After the structured-educational intervention, there were significant improvements in parent’s awareness, knowledge, and perceptions of HPV infection, cervical cancer, and HPV vaccination (all p < 0.001). HPV vaccine’s acceptability increased from 74.3 to 87.4% (p < 0.001). There was a significant correlation between increasing HPV vaccine acceptability with the improvement of awareness, knowledge, and perception toward HPV infection, cervical cancer and HPV vaccination (r = 0.32 to 0.53, p < 0.001). After the structured-educational intervention, better knowledge and positive perceptions of HPV vaccination were predictive of HPV vaccine’s acceptability with OR 1.90 (95%CI:1.40–2.57) and OR 1.31(95%CI,1.05–1.63), respectively. Conclusions A structured-educational intervention may improve parental awareness, knowledge, and perceptions toward HPV and the acceptability of the vaccine. Further study, a randomized control trial with longer follow-up are needed to evaluate the long-term and actual effectiveness of improving parents’ knowledge, perceptions and HPV vaccine acceptability.

scholarly journals Improvement of Parent’s Awareness, Knowledge, Perception, and Acceptability of HPV Vaccination After a Structured-educational Intervention

2020 ◽  
Author(s):  
Mei Neni Sitaresmi ◽  
Nisrina Maulida Rozanti ◽  
Lamria Besty Simangunsong ◽  
Abdul Wahab
Keyword(s):  
Educational Intervention ◽  
Hpv Vaccine ◽  
Hpv Vaccination ◽  
Hpv Infection ◽  
Primary School Students ◽  
School Students ◽  
Demonstration Program ◽  
Vaccine Acceptability ◽  
Parental Awareness ◽  
Hpv Vaccine Acceptability

Abstract Background: Regardless of the disease burden of human papillomavirus (HPV), the vaccine has not been included in the Indonesia National Immunization Program. Since 2017 there was a demonstration program of the HPV vaccination in Yogyakarta Province. This vaccine was given free to female primary school students in the 5 th and 6 th grades (11-13 years old). This study aimed to assess whether a structured-educational intervention focus on HPV increases the parental awareness, knowledge, and perceptions toward HPV and the vaccine acceptability. Methods: We conducted a pre-post structured-educational intervention study from July to August 2017 before the implementation of the HPV vaccination demonstration program, in Kulon Progo District, Yogyakarta Province, Indonesia. Parents of female primary school students grades 5 th and 6 th were selected using a school-based proportional random sampling. A pediatric resident provided a structured-educational intervention, which consists of the burden and risk of HPV disease, as well as the benefit and safety of the vaccine. Parents were required to complete validated self-administered questionnaires before and after the structured-educational intervention. Results: A total of 506 parents participated. Before receiving the structured-educational intervention, parents' awareness of HPV infection and the vaccines were low. Only 49.2% of parents had heard HPV infection, and 48.8% had heard about the vaccine. After the structured-educational intervention, there were significant improvements in parent’s awareness, knowledge, and perceptions of HPV infection, cervical cancer, and HPV vaccination (all p <0.001). HPV vaccine's acceptability increased from 74.3% to 87.4% ( p <0.001). There was a significant correlation between increasing HPV vaccine acceptability with the improvement of awareness, knowledge, and perception toward HPV infection, cervical cancer and HPV vaccination (r=0.32 to 0.53, p <0.001). After the structured-educational intervention, better knowledge and positive perceptions of HPV vaccination were predictive of HPV vaccine's acceptability with OR 1.90 (95%CI:1.40-2.57) and OR 1.31(95%CI:1.05-1.63), respectively. Conclusions: A structured-educational intervention may improve parental awareness, knowledge, and perceptions toward HPV and the acceptability of the vaccine. Further study, a randomized control trial with longer follow-up are needed to evaluate the long-term and actual effectiveness of improving parents’ knowledge, perceptions and HPV vaccine acceptability .

scholarly journals Improvement of Parent’s Awareness, Knowledge, Perception, and Acceptability of HPV Vaccination After a Structured-educational Intervention

2020 ◽  
Author(s):  
Mei Neni Sitaresmi ◽  
Nisrina Maulida Rozanti ◽  
Lamria Besty Simangunsong ◽  
Abdul Wahab
Keyword(s):  
Educational Intervention ◽  
Hpv Vaccine ◽  
Hpv Vaccination ◽  
Hpv Infection ◽  
Primary School Students ◽  
School Students ◽  
Demonstration Program ◽  
Vaccine Acceptability ◽  
Parental Awareness ◽  
Hpv Vaccine Acceptability

Abstract Background: Regardless of the disease burden of human papillomavirus (HPV), the vaccine has not been included in the Indonesia National Immunization Program. Since 2017 there was a demonstration program of the HPV vaccination in Yogyakarta Province. This vaccine was given free to female primary school students in the 5th and 6th grades (11-13 years old). This study aimed to assess whether a structured-educational intervention focus on HPV increases the parental awareness, knowledge, and perceptions toward HPV and the vaccine acceptability.Methods: We conducted a pre-post structured-educational intervention study from July to August 2017 before the implementation of the HPV vaccination demonstration program, in Kulon Progo District, Yogyakarta Province, Indonesia. Parents of female primary school students grades 5th and 6th were selected using a school-based proportional random sampling. A pediatric resident provided a structured-educational intervention, which consists of the burden and risk of HPV disease, as well as the benefit and safety of the vaccine. Parents were required to complete validated self-administered questionnaires before and after the structured-educational intervention. Results: A total of 506 parents participated. Before receiving the structured-educational intervention, parents' awareness of HPV infection and the vaccines were low. Only 49.2% of parents had heard HPV infection, and 48.8% had heard about the vaccine. After the structured-educational intervention, there were significant improvements in parent’s awareness, knowledge, and perceptions of HPV infection, cervical cancer, and HPV vaccination (all p<0.001). HPV vaccine's acceptability increased from 74.3% to 87.4% (p<0.001). There was a significant correlation between increasing HPV vaccine acceptability with the improvement of awareness, knowledge, and perception toward HPV infection, cervical cancer and HPV vaccination (r=0.32 to 0.53, p<0.001). After the structured-educational intervention, better knowledge and positive perceptions of HPV vaccination were predictive of HPV vaccine's acceptability with OR 1.90 (95%CI:1.40-2.57) and OR 1.31(95%CI:1.05-1.63), respectively. Conclusions: A structured-educational intervention may improve parental awareness, knowledge, and perceptions toward HPV and the acceptability of the vaccine. Further study, a randomized control trial with longer follow-up are needed to evaluate the long-term and actual effectiveness of improving parents’ knowledge, perceptions and HPV vaccine acceptability.

scholarly journals Immunogenicity of 2 and 3 Doses of the Quadrivalent Human Papillomavirus Vaccine up to 120 Months Postvaccination: Follow-up of a Randomized Clinical Trial

2019 ◽  
Vol 71 (4) ◽  
pp. 1022-1029 ◽  
Author(s):  
Robine Donken ◽  
Simon R M Dobson ◽  
Kim D Marty ◽  
Darrel Cook ◽  
Chantal Sauvageau ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Hpv Vaccine ◽  
Geometric Mean ◽  
Hpv Vaccination ◽  
Study Groups ◽  
Vaccination Schedule ◽  
Quadrivalent Vaccine ◽  
Adult Women ◽  
Human Papillomavirus Vaccine ◽  
Vaccine Schedule

Abstract Background Several countries have implemented a 2-dose (2D) human papillomavirus (HPV) vaccination schedule for adolescents based on immunobridging studies. We compared immunogenicity of 2D vs 3-dose (3D) schedules of the quadrivalent vaccine (4vHPV) up to 10 years after the first dose. Methods Girls aged 9–13 years were randomized to receive 2D or 3D and were compared with women aged 16–26 receiving 3D at day 1 and months 7, 24, and 120 after the first dose. Antibody levels for HPV6/11/16/18 were evaluated using the competitive Luminex immunoassay (cLIA) and total immunoglobulin G assay. Geometric mean titers (GMTs) and seropositivity rates were compared between the different groups at different time points. Noninferiority of GMT ratios was defined as the lower bound of the 2-sided 95% confidence interval (CI) being greater than 0.5. Kinetics of antibody titers over time among study groups were examined. Results At 120 months, data from 35 2D girls, 38 3D girls, and 30 3D women were used for analyses. cLIA seropositivity rates were above 95% for all HPV vaccine types and all schedules, except HPV18, with the lowest seropositivity observed among 3D women (60.0%; 95% CI, 40.6%–77.3%). GMT ratios (cLIA) for both 2D and 3D girls were noninferior to 3 doses in women for HPV6/11/16/18. Trends were comparable between assays. Conclusions GMTs for HPV6/11/16/18 after 2D or 3D of 4vHPV in girls were noninferior to 3D in adult women up to 120 months postvaccination. This study demonstrates long-term immunogenicity of the 2D HPV vaccine schedule.

Human papillomavirus vaccine acceptability among a national sample of adult women in the USA

Sexual Health ◽  
2010 ◽  
Vol 7 (3) ◽  
pp. 304 ◽  
Author(s):  
Nathan W. Stupiansky ◽  
Susan L. Rosenthal ◽  
Sarah E. Wiehe ◽  
Gregory D. Zimet
Keyword(s):  
Human Papillomavirus ◽  
Sexual Health ◽  
Health Outcomes ◽  
Hpv Vaccine ◽  
Adult Women ◽  
Vaccine Acceptability ◽  
Vaccine Cost ◽  
Health Related ◽  
The Usa ◽  
Hpv Vaccine Acceptability

Background: In the USA, the human papillomavirus (HPV) vaccine is currently licensed for 9–26-year-old females, but licensure for women over 26 years is being considered. The aim of the current study was to investigate the association of sociodemographic and health-related factors to HPV vaccine acceptability among adult women. Methods: The current study utilised a nationally representative sample of women (n = 1323) aged 27–55 living in the USA, with an oversampling of black and Latina women. A multiple item measure of HPV vaccine acceptability across varying cost and location-of-availability (clinic only v. any local pharmacy) conditions was the main outcome measure. General linear modelling was used to analyse the association of vaccine cost, location availability, and sociodemographic and health-related variables with vaccine acceptability. Results: Vaccine cost had the strongest association with acceptability [F (2, 1249) = 832.1; P < 0.0001]; however, factors such as religiosity, political views, a history of various negative sexual health outcomes and previous flu shot receipt were also associated with acceptability. Location availability had a statistically significant but modest effect, with a slight preference shown for health clinic availability. Conclusions: Adult women had generally high levels of HPV vaccine acceptability, but were greatly influenced by cost of the vaccine. Women who had experienced negative sexual health outcomes due to HPV-specific infection rated the vaccine as more acceptable, perhaps due to distress associated with those outcomes.

scholarly journals Vaccine Effectiveness Against Prevalent Anal and Oral Human Papillomavirus Infection Among Men Who Have Sex With Men—United States, 2016–2018

2020 ◽  
Vol 222 (12) ◽  
pp. 2052-2060
Author(s):  
Elissa Meites ◽  
Rachel L Winer ◽  
Michael E Newcomb ◽  
Pamina M Gorbach ◽  
Troy D Querec ◽  
...  
Keyword(s):  
United States ◽  
Human Papillomavirus ◽  
Young Adult ◽  
Hpv Vaccine ◽  
Hpv Vaccination ◽  
Vaccine Effectiveness ◽  
Quadrivalent Vaccine ◽  
Hpv Prevalence ◽  
Vaccine Type ◽  
Sex With Men

Abstract Background In the United States, human papillomavirus (HPV) vaccination has been recommended for young adult men who have sex with men (MSM) since 2011. Methods The Vaccine Impact in Men study surveyed MSM and transgender women aged 18–26 years in 3 US cities during 2016–2018. Self-collected anal swab and oral rinse specimens were assessed for 37 types of HPV. We compared HPV prevalence among vaccinated and unvaccinated participants and determined adjusted prevalence ratios (aPR) and 95% confidence intervals (CI). Results Among 1767 participants, 704 (39.8%) self-reported receiving HPV vaccine. Median age at vaccination (18.7 years) was older than age at first sex (15.7 years). Quadrivalent vaccine-type HPV was detected in anal or oral specimens from 475 (26.9%) participants. Vaccine-type HPV prevalence was lower among vaccinated (22.9%) compared with unvaccinated (31.6%) participants; aPR for those who initiated vaccination at age ≤18 years was 0.41 (CI, 0.24–0.57) and at age &gt;18 years was 0.82 (CI, 0.67–0.98). Vaccine effectiveness of at least 1 HPV vaccine dose at age ≤18 years or &gt;18 years was 59% and 18%, respectively. Conclusions Findings suggest real-world effectiveness of HPV vaccination among young adult MSM. This effect was stronger with younger age at vaccination.

Barriers to Cervical Cancer Screening and Prevention in Young Korean Immigrant Women: Implications for Intervention Development

2016 ◽  
Vol 28 (4) ◽  
pp. 353-362 ◽  
Author(s):  
Hee Yun Lee ◽  
Mi Hwa Lee
Keyword(s):  
Cervical Cancer ◽  
Hpv Vaccine ◽  
Cancer Education ◽  
Immigrant Women ◽  
Hpv Vaccination ◽  
Pap Test ◽  
Korean Immigrant ◽  
Vaccine Acceptability ◽  
Korean Immigrant Women ◽  
Hpv Vaccine Acceptability

This study aimed to identify major barriers to Papanicolaou (Pap) test uptake and human papillomavirus (HPV) vaccine acceptability. Three focus groups with 16 young Korean immigrant women residing in a community in the Midwest were conducted. Braun and Clarke’s six phases of thematic analysis were used to develop themes. Three major themes emerged as barriers: (a) limited knowledge about cervical cancer and preventive behaviors, (b) culture-specific barriers, and (c) low accessibility to health care services. These themes were multifactorial and interrelated barriers to Pap test uptake and HPV vaccine acceptability among young Korean immigrant women. These findings indicate that culturally tailored cervical cancer education is needed to promote Pap test uptake and HPV vaccination in this underserved population.

scholarly journals Feasibility of a Coordinated Human Papillomavirus (HPV) Vaccination Program between a Medical Clinic and a Community Pharmacy

Pharmacy ◽  
2019 ◽  
Vol 7 (3) ◽  
pp. 91 ◽  
Author(s):  
Doucette ◽  
Kent ◽  
Seegmiller ◽  
McDonough ◽  
Evans
Keyword(s):  
Human Papillomavirus ◽  
Community Pharmacy ◽  
Hpv Vaccine ◽  
Hpv Vaccination ◽  
Initial Study ◽  
Vaccination Program ◽  
Medical Clinic ◽  
Coordinated Care ◽  
Medical Clinics ◽  
To Receive

Human papillomavirus (HPV) vaccination coverage could be enhanced by community pharmacies working with medical clinics to coordinate completion of the HPV vaccination series. The objective for this study was to assess the feasibility of a coordinated model of HPV vaccine delivery in which a clinic gives the first dose and refers patients to a partnering community pharmacy to receive subsequent doses. A medical clinic-community pharmacy team was established in a Midwestern state to develop and operate a coordinated care model for HPV vaccinations. Under the coordinated model, the clinic identified patients needing HPV vaccination(s), administered the first dose and described the option to complete the vaccination series at the pharmacy. Interested patients then had an information sheet faxed and electronic prescriptions sent to the pharmacy. The pharmacy contacted the patients to schedule administration of 2nd and 3rd doses of the HPV vaccine. Over a 12-month period, 51 patients were referred to the pharmacy by the clinic. Of these, 23 patients received a total of 25 vaccinations. Clinic and pharmacy personnel mostly rated the coordinated program favorably. An initial study of a coordinated HPV vaccination program between a medical clinic and a community pharmacy supported patients getting HPV vaccinations.

Sign in / Sign up

Export Citation Format

Share Document